Prostate cancer is a major and increasing public health burden. Androgen suppression therapy (AST) for prostate cancer provides well-established benefits in advanced stages of the disease. Unfortunately, mounting evidence suggests an association between AST and increased risk of cardiovascular disease (CVD). In this viewpoint, the authors seek to raise awareness of an underappreciated problem, summarise the evidence linking AST and CVD risk, and highlight important research questions that need to be addressed. Given the lack of a clear evidence base with which to dictate, the authors discuss possible management options and how these might be integrated into existing care pathways.
Statistics from Altmetric.com
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.